Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xueshuantong for Injection
- Development stage
- Phase 4
- Lead developer
- Wuzhou Zhongheng
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Xueshuantong for Injection (also known as freeze-dried Xueshuantong for Injection) is a standardized traditional Chinese medicine (TCM) and botanical drug preparation primarily composed of Panax notoginseng saponins (PNS), with major active constituents including ginsenoside Rg1, ginsenoside Rb1, notoginsenoside R1, ginsenoside Re, and ginsenoside Rd. Developed and manufactured by Guangxi Wuzhou Pharmaceutical, it is widely approved and used in China as an intravenous therapy to promote blood circulation, resolve blood stasis, and improve microcirculation. Its primary clinical indications include ischemic cardiovascular and cerebrovascular diseases, such as acute cerebral infarction, stroke hemiplegia, and unstable angina pectoris, as well as retinal vein occlusion.
- Brand names
- Xueshuantong
- Other names
- PNSPanax notoginseng saponinsXSTXueshuantong (lyophilized) for injectionXueshuantong Injectionfreeze-dried Xueshuantong for Injection注射用血栓通（冻干）
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)EGFR (Epidermal growth factor receptor)IL1B (Interleukin-1 beta)PFK (Phosphofructokinase-1 liver type)VEGFA (Vascular endothelial growth factor A)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on Xueshuantong for Injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xueshuantong for Injection.